Research programme: topical wound treatment - AlphaRx

Drug Profile

Research programme: topical wound treatment - AlphaRx

Alternative Names: ARX606T

Latest Information Update: 23 Sep 2011

Price : $50

At a glance

  • Originator AlphaRx
  • Developer AlphaRx; Riso Pharma Tech
  • Class Growth factors
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Wounds

Most Recent Events

  • 05 Jul 2011 Discontinued - Preclinical for Wounds in Canada (Topical)
  • 30 Sep 2009 Preclinical trials in Wounds in Canada (Topical)
  • 30 Sep 2009 ARX 606T licensed to Riso Pharma Tech worldwide (excluding Asia) for the treatment of Wounds
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top